United Therapeutics Co. (UTHR) Holdings Reduced by AMP Capital Investors Ltd

AMP Capital Investors Ltd cut its position in United Therapeutics Co. (NASDAQ:UTHR) by 12.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,337 shares of the biotechnology company’s stock after selling 9,977 shares during the period. AMP Capital Investors Ltd owned 0.16% of United Therapeutics worth $8,008,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in UTHR. HPM Partners LLC lifted its position in shares of United Therapeutics by 0.8% during the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares in the last quarter. First Allied Advisory Services Inc. lifted its position in shares of United Therapeutics by 0.4% during the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after purchasing an additional 19 shares in the last quarter. Synovus Financial Corp lifted its position in shares of United Therapeutics by 1.2% during the second quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after purchasing an additional 69 shares in the last quarter. Ifrah Financial Services Inc. lifted its position in shares of United Therapeutics by 1.7% during the second quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 76 shares in the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of United Therapeutics by 2.3% during the second quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 86 shares in the last quarter.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 7,061 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $121.12, for a total value of $855,228.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $116.07, for a total transaction of $147,873.18. Following the completion of the sale, the chief executive officer now directly owns 2,343 shares of the company’s stock, valued at approximately $271,952.01. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,669 shares of company stock valued at $2,755,543. 7.80% of the stock is currently owned by insiders.

Shares of United Therapeutics Co. (NASDAQ UTHR) opened at $135.22 on Wednesday. The firm has a market cap of $5,885.78, a P/E ratio of 12.01 and a beta of 1.42. United Therapeutics Co. has a 12 month low of $112.01 and a 12 month high of $169.89.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.23 earnings per share. equities analysts anticipate that United Therapeutics Co. will post 12.45 EPS for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. TheStreet lowered shares of United Therapeutics from a “b-” rating to a “c” rating in a research report on Friday, September 29th. Cowen reiterated a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a research report on Friday, October 27th. HC Wainwright reiterated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research report on Thursday, October 26th. Finally, BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $136.10.

TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.com-unik.info/2017/12/13/united-therapeutics-co-uthr-holdings-reduced-by-amp-capital-investors-ltd.html.

United Therapeutics Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit